MYRIAD GENETICS INC
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
MYGN$5.67-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity for
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)
| Commonstock | Additionalpaid-incapital | Accumulatedothercomprehensiveloss | Accumulateddeficit | Myriad Genetics, Inc.Stockholders’equity | |
|---|---|---|---|---|---|
| BALANCES AT DECEMBER 31, 2022 | $0.8 | $1,260.1 | $(8.9) | $(366.2) | $885.8 |
| Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax | — | (4.9) | — | — | (4.9) |
| Stock-based payment expense | — | 7.5 | — | — | 7.5 |
| Net loss | — | — | — | (54.7) | (54.7) |
| Other comprehensive income, net of tax | — | — | 1.5 | — | 1.5 |
| BALANCES AT MARCH 31, 2023 | $0.8 | $1,262.7 | $(7.4) | $(420.9) | $835.2 |
| BALANCES AT DECEMBER 31, 2023 | $0.9 | $1,415.5 | $(3.7) | $(629.5) | $783.2 |
| Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax | — | (8.7) | — | — | (8.7) |
| Stock-based payment expense | — | 12.0 | — | — | 12.0 |
| Net loss | — | — | — | (26.0) | (26.0) |
| Other comprehensive loss, net of tax | — | — | (0.5) | — | (0.5) |
| BALANCES AT MARCH 31, 2024 | $0.9 | $1,418.8 | $(4.2) | $(655.5) | $760.0 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.